Discounted Cash Flow (DCF) Analysis Levered

CymaBay Therapeutics, Inc. (CBAY)

$3.4

-0.14 (-3.95%)
All numbers are in Millions, Currency in USD

Free Cash Flow

Year
A/P
2017
Actual
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 10---------
Revenue (%)
Operating Cash Flow -19.63---------
Operating Cash Flow (%)
Capital Expenditure -0.03---------
Capital Expenditure (%)
Free Cash Flow -19.66---------

Weighted Average Cost Of Capital

Share price $ 3.4
Beta 0.614
Diluted Shares Outstanding 69.02
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 6.595
Total Debt -
Total Equity 234.68
Total Capital 234.68
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash Flow

Year
A/P
2017
Actual
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 10---------
Operating Cash Flow -19.63---------
Capital Expenditure -0.03---------
Free Cash Flow -19.66---------
WACC
PV LFCF ---------
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 6.60
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -125.81
Equity Value -
Shares Outstanding 69.02
Equity Value Per Share -